S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Curis Stock Price, News & Analysis (NASDAQ:CRIS)

$2.06
-0.08 (-3.74 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$2.06
Now: $2.06
$2.17
50-Day Range
$1.87
MA: $2.15
$2.53
52-Week Range
$0.60
Now: $2.06
$2.90
Volume77,158 shs
Average Volume135,634 shs
Market Capitalization$68.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.43 million
Book Value($0.14) per share

Profitability

Net Income$-32,580,000.00
Net Margins-307.75%

Miscellaneous

Employees55
Market Cap$68.39 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.


Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

When did Curis' stock split? How did Curis' stock split work?

Curis's stock reverse split on the morning of Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. The biotechnology company earned $2.09 million during the quarter. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Curis.

Has Curis been receiving favorable news coverage?

Media stories about CRIS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Curis earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Curis.

Are investors shorting Curis?

Curis saw a decline in short interest in September. As of September 30th, there was short interest totalling 287,500 shares, a decline of 41.2% from the August 30th total of 489,100 shares. Based on an average trading volume of 199,600 shares, the short-interest ratio is presently 1.4 days. Approximately 1.1% of the company's shares are short sold. View Curis' Current Options Chain.

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (Cldx), Micron Technology (MU), Novavax (NVAX), Zynga (ZNGA), Synergy Pharmaceuticals (SGYP), Jones Energy (JONE), CTI BioPharma (CTIC), Agenus (AGEN) and Idera Pharmaceuticals (IDRA).

Who are Curis' key executives?

Curis' management team includes the folowing people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 52)
  • Dr. Robert E. Martell, Head of R&D (Age 56)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)
  • Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58)

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $2.06.

How big of a company is Curis?

Curis has a market capitalization of $68.39 million and generates $10.43 million in revenue each year. Curis employs 55 workers across the globe.View Additional Information About Curis.

What is Curis' official website?

The official website for Curis is http://www.curis.com/.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]ris.com.


MarketBeat Community Rating for Curis (NASDAQ CRIS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  533 (Vote Outperform)
Underperform Votes:  465 (Vote Underperform)
Total Votes:  998
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel